Jane Street
BCRX icon

Jane Street’s BioCryst Pharmaceuticals BCRX Stock Holding History

Jane Street’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.19M Buy
545,036
+4,936
+0.9% +$38.3K ﹤0.01% 3458
2025
Q4 		$4.21M Buy
540,100
+6,200
+1% +$44.8K ﹤0.01% 3503
2025
Q3 		$4.05M Sell
533,900
-123,600
-19% -$1.03M ﹤0.01% 3730
2025
Q2 		$5.89M Buy
657,500
+126,000
+24% +$1.17M ﹤0.01% 2788
2025
Q1 		$3.99M Buy
531,500
+455,000
+595% +$3.67M ﹤0.01% 3270
2024
Q4 		$575K Sell
76,500
-12,200
-14% -$92.6K ﹤0.01% 6497
2024
Q3 		$674K Sell
88,700
-1,900
-2% -$14.4K ﹤0.01% 6655
2024
Q2 		$560K Buy
90,600
+14,700
+19% +$81.1K ﹤0.01% 6838
2024
Q1 		$386K Sell
75,900
-213,300
-74% -$1.2M ﹤0.01% 7147
2023
Q4 		$1.73M Sell
289,200
-8,800
-3% -$51K ﹤0.01% 4587
2023
Q3 		$2.11M Buy
298,000
+139,200
+88% +$1M ﹤0.01% 3972
2023
Q2 		$1.12M Sell
158,800
-28,200
-15% -$226K ﹤0.01% 5033
2023
Q1 		$1.56M Sell
187,000
-203,100
-52% -$1.96M ﹤0.01% 4238
2022
Q4 		$4.48M Sell
390,100
-217,700
-36% -$2.71M ﹤0.01% 2646
2022
Q3 		$7.66M Buy
607,800
+67,400
+12% +$867K ﹤0.01% 2008
2022
Q2 		$5.72M Sell
540,400
-213,300
-28% -$2.2M ﹤0.01% 2470
2022
Q1 		$12.3M Buy
753,700
+235,100
+45% +$3.77M ﹤0.01% 1737
2021
Q4 		$7.18M Sell
518,600
-132,600
-20% -$1.75M ﹤0.01% 2320
2021
Q3 		$9.36M Buy
651,200
+73,600
+13% +$1.16M ﹤0.01% 1879
2021
Q2 		$9.13M Sell
577,600
-65,100
-10% -$885K ﹤0.01% 1836
2021
Q1 		$6.54M Buy
642,700
+291,000
+83% +$3M ﹤0.01% 2033
2020
Q4 		$2.62M Buy
351,700
+211,200
+150% +$1.09M ﹤0.01% 3042
2020
Q3 		$483K Sell
140,500
-122,400
-47% -$525K ﹤0.01% 5204
2020
Q2 		$1.25M Buy
+262,900
New +$1.05M ﹤0.01% 3740
2017
Q3 		– Sell
-85,700
Closed -$476K – 4435
2017
Q2 		$476K Buy
85,700
+72,700
+559% +$443K ﹤0.01% 3093
2017
Q1 		$109K Buy
13,000
+2,300
+21% +$16K ﹤0.01% 3963
2016
Q4 		$68K Buy
+10,700
New +$55.7K ﹤0.01% 3913
2015
Q4 		– Sell
-17,100
Closed -$195K – 3981
2015
Q3 		$195K Buy
+17,100
New +$228K ﹤0.01% 3200

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Jane Street's BCRX Position: Q1 2026 in Review

Jane Street reduced its BioCryst Pharmaceuticals (BCRX) stake by 4.1% in Q1 2026, selling an estimated $208K and leaving 622,607 shares worth $5.93M. The position accounts for ﹤0.01% of the portfolio, ranked #3259.

Jane Street first reported a position in BCRX in Q2 2013 and has held it in 36 quarters since. The position peaked at $14M in Q3 2025. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Jane Street held 622,607 shares of BioCryst Pharmaceuticals worth $5.93M as of Q1 2026.
  • Jane Street sold 26,750 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $208K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #3259 holding.
  • Jane Street first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 36 quarters since.
  • Jane Street's BioCryst Pharmaceuticals position peaked at $14M in Q3 2025.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.